Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Vera Therapeutics, Inc.
VERA·Healthcare
C ★★Sell
Current$29.79
Nov 8, 2026

Vera Therapeutics has a differentiated FDA-approved IgAN therapy with promising commercial potential, but high cash burn, dilution, and uncertain launch economics challenge the sustainability of shareholder returns.

Score
56
nLIGHT, Inc.
LASR·Technology
C ★★Sell
Current$38.02
Nov 8, 2026

nLIGHT offers substantial long-term growth potential in directed-energy defense through proprietary laser technology and major contracts, but demanding valuation, execution uncertainty, and persistent shareholder dilution limit its investment appeal.

Score
56
Westlake Corporation
WLK·Materials
C ★★Sell
Current$63.49
Nov 7, 2026

Westlake offers cyclical recovery potential through integrated chemicals, housing products, and cost restructuring, but weak capital returns, minimal free cash flow, and global petrochemical oversupply constrain its investment appeal.

Score
56
Cytokinetics, Incorporated
CYTK·Healthcare
C ★★Sell
Current$53.69
Nov 7, 2026

Cytokinetics has a promising cardiac myosin inhibitor franchise with accelerating MYQORZO sales and new indication opportunities, but high operating losses, financing claims, and demanding valuation expectations constrain investment attractiveness.

Score
56
Charles River Laboratories International, Inc.
CRL·Healthcare
C ★★Sell
Current$337.52
Nov 7, 2026

Charles River Laboratories benefits from durable regulated testing demand and improving laboratory utilization, but its demanding valuation and declining free cash flow limit the investment appeal despite operational recovery.

Score
56
Louisiana-Pacific Corporation
LPX·Industrials
C ★★Sell
Current$76.97
Nov 6, 2026

Louisiana-Pacific's differentiated SmartSide franchise offers long-term market-share and margin potential, but persistent OSB losses, weak free cash flow, and demanding valuation constrain near-term investment attractiveness.

Score
56
Pinnacle West Capital Corporation
PNW·Utilities
C ★★Sell
Current$103.83
Nov 6, 2026

Pinnacle West benefits from a protected Arizona utility franchise and accelerating industrial electricity demand, but premium valuation, heavy capital spending, and regulatory recovery uncertainty constrain shareholder upside.

Score
56
Teva Pharmaceutical Industries Limited
TEVA·Healthcare
C ★★Sell
Current$41.78
Nov 6, 2026

Teva's innovative medicines and deleveraging support a credible pharmaceutical turnaround, but its substantial rerating, persistent generic erosion, and demanding cash-flow expectations weaken the investment case.

Score
56
Valaris Limited
VAL·Energy
C ★★Sell
Current$82.77
Nov 5, 2026

Valaris offers improving deepwater utilization and a potentially valuable Transocean merger, but persistent negative free cash flow, cyclical drilling demand and fixed-ratio transaction exposure weaken its risk-adjusted appeal.

Score
56
Cameco Corporation
CCJ·Energy
C ★★Sell
Current$76.85
Nov 2, 2026

Cameco offers scarce uranium resources, long-term nuclear fuel demand, and Westinghouse exposure, but weak cash conversion and demanding valuation multiples create substantial downside risk if operating recovery disappoints.

Score
56
STMicroelectronics N.V.
STM·Technology
C ★★Sell
Current$46.74
Nov 1, 2026

STMicroelectronics offers a credible cyclical recovery in embedded processing and semiconductor manufacturing, but demanding valuation, weak capital returns, and persistent power-device losses limit its investment appeal.

Score
56